Griffin Securities (“Griffin”), a research-driven investment banking firm, has released an industry report on the subject of targeting cancer stem cells (CSCs). The stem cell hypothesis offers a rational approach to preventing, diagnosing, and treating malignant growth. Covered in the report are five classes of drugs nearing the Phase II clinical trial that provides human proof-of concept data, a crucial stage of development: Notch signaling, P13k/akt pathway, immunotherapeutics, molecular chaperons, and hedgehog signaling.

Companies highlighted in the write up include: Bristol Myers Squibb Co. (Public), Calistoga Pharmaceuticals (private), Champions Biotechnology Inc. (Public, OTC:CSBR), Curis, Inc. (Public), Exelixis, Inc., Genentech (private), ImmunoCellular Therapeutics, Ltd. (Public), Infinity Pharmaceuticals Inc. (Public), Keryx Biopharmaceuticals (Public, MabCure Inc (Public, OTC:MBCI), Merck & Co., Inc. (Public), Myriad Pharmaceuticals, Inc. (Public), Novartis AG (ADR) (Public), OncoMed Pharmaceuticals (private), Oncothyreon Inc. (Public), Pfizer Inc. (Public), Rexahn Pharmaceuticals, Inc. (Public), Roche Holding Ltd. (ADR) (Public), Synta Pharmaceuticals Corp. (Public), and Trojantec (Private).

The report can be downloaded by clicking on the link below: http://www.griffinsecurities.com/pdf/Industry_Reports/Griffin_Industry_Report_-_Targeting_Cancer_Stem_Cells_14Sep09.pdf

About Griffin Securities

Griffin Securities is a research-driven investment banking firm providing corporate finance, merger & acquisitions, brokerage, and investment opportunities for institutional, corporate, and private clients. The firm is a member of the Financial Industry Regulatory Authority (FINRA) (www.finra.org) and the Securities Investor Protection Corporation (SIPC) (www.sipc.org). Griffin Securities is headquartered in New York City and has no other domestic or international affiliates or subsidiaries.

FORWARD-LOOKING STATEMENTS: The Report contains forward-looking statements, which involve risks and uncertainties. Actual results may differ significantly from such forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the “Risk Factors” section in the SEC filings available in electronic format through SEC Edgar filings at www.sec.gov on t

MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more MabCure (CE) Charts.
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more MabCure (CE) Charts.